Refaat M, Abdullatif AM, Hamza MM, et al. - Researchers conducted the study for analyzing the safety of extended monthly intravitreal infliximab injections in patients with active posterior uveitis in Behcet's disease. This is a prospective, interventional, noncomparative, open-label, pilot study of 9 monthly intravitreal infliximab injections (1 mg/0.05 mL) for 22 eyes of 16 Behcet's disease patients with active posterior uveitis. Treatment was successful in 7 eyes (35%), while failure occurred in 13 eyes (65%). Intravitreal infliximab for active posterior uveitis in Behcet's disease was linked to a high complication rate and a failure to control inflammation in the majority of eyes. It should not be used in place of systemic therapy.